TB vaccine development: where are we and why is it so difficult?

The development of an effective TB vaccine remains paramount to achieving the goal of global eradication of TB by 2050. The only licensed vaccine, BCG, has variable efficacy and is poorly effective in high burden countries. The development of promising candidate vaccines to either ‘boost’ a BCG prim...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilkie, Morven E M, McShane, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Chest Clinic
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345977/
https://www.ncbi.nlm.nih.gov/pubmed/25432943
http://dx.doi.org/10.1136/thoraxjnl-2014-205202
_version_ 1782359661907804160
author Wilkie, Morven E M
McShane, Helen
author_facet Wilkie, Morven E M
McShane, Helen
author_sort Wilkie, Morven E M
collection PubMed
description The development of an effective TB vaccine remains paramount to achieving the goal of global eradication of TB by 2050. The only licensed vaccine, BCG, has variable efficacy and is poorly effective in high burden countries. The development of promising candidate vaccines to either ‘boost’ a BCG primed immune system or replace BCG altogether is a key area for innovative research. Here, we discuss some of the issues encountered in the development of potential candidate vaccines and the future challenges.
format Online
Article
Text
id pubmed-4345977
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-43459772015-03-18 TB vaccine development: where are we and why is it so difficult? Wilkie, Morven E M McShane, Helen Thorax Chest Clinic The development of an effective TB vaccine remains paramount to achieving the goal of global eradication of TB by 2050. The only licensed vaccine, BCG, has variable efficacy and is poorly effective in high burden countries. The development of promising candidate vaccines to either ‘boost’ a BCG primed immune system or replace BCG altogether is a key area for innovative research. Here, we discuss some of the issues encountered in the development of potential candidate vaccines and the future challenges. BMJ Publishing Group 2015-03 2014-11-28 /pmc/articles/PMC4345977/ /pubmed/25432943 http://dx.doi.org/10.1136/thoraxjnl-2014-205202 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
spellingShingle Chest Clinic
Wilkie, Morven E M
McShane, Helen
TB vaccine development: where are we and why is it so difficult?
title TB vaccine development: where are we and why is it so difficult?
title_full TB vaccine development: where are we and why is it so difficult?
title_fullStr TB vaccine development: where are we and why is it so difficult?
title_full_unstemmed TB vaccine development: where are we and why is it so difficult?
title_short TB vaccine development: where are we and why is it so difficult?
title_sort tb vaccine development: where are we and why is it so difficult?
topic Chest Clinic
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345977/
https://www.ncbi.nlm.nih.gov/pubmed/25432943
http://dx.doi.org/10.1136/thoraxjnl-2014-205202
work_keys_str_mv AT wilkiemorvenem tbvaccinedevelopmentwhereareweandwhyisitsodifficult
AT mcshanehelen tbvaccinedevelopmentwhereareweandwhyisitsodifficult

Ejemplares similares